利奈唑胺治疗新生儿感染性疾病的研究进展

发布时间：2019-03-23 19:53

【摘要】：目的:了解利奈唑胺治疗新生儿感染性疾病的研究进展。方法:查阅近年来国内外相关文献,就利奈唑胺的作用机制、药动学特征和在新生儿感染性疾病中的应用的研究进行归纳和总结。结果和结论:利奈唑胺未被完全批准用于新生儿,但多项研究显示出利奈唑胺治疗新生儿耐药革兰氏阳性菌感染安全、有效,尤其是对新生儿败血症的治疗,利奈唑胺与万古霉素疗效相当。在新生儿中,利奈唑胺的给药可根据疾病、出生时体质量、胎龄和日龄等因素选择给药方案。新生儿中利奈唑胺的不良反应发生率较万古霉素低,但由于会引起骨髓抑制,用药期间需密切监测全血细胞计数。我国尚需大样本的研究用于评估利奈唑胺在新生儿感染性疾病治疗中的疗效和安全性。
[Abstract]:Objective: to investigate the progress in the treatment of neonatal infectious diseases with linidazole. Methods: referring to the related literatures at home and abroad in recent years, the mechanism, pharmacokinetic characteristics and application in neonatal infectious diseases were summarized and summarized. Results and conclusion: Linezolide has not been fully approved for neonatal use, but several studies have shown that it is safe and effective in the treatment of neonatal drug-resistant gram-positive bacteria infection, especially for neonatal septicemia. Linezolamine and vancomycin have the same therapeutic effect. In newborns, the administration of linazolamide can be selected according to the disease, birth weight, gestational age and age. The incidence of adverse reactions in newborn infants was lower than that of vancomycin, but the whole blood cell count should be closely monitored during the treatment because of myelosuppression. In our country, a large sample study is needed to evaluate the efficacy and safety of linazolamide in the treatment of neonatal infectious diseases.
【作者单位】：安徽医科大学第三附属医院药学部;
【分类号】：R722.13

【参考文献】